{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": null, "lead_paragraph": "Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick.", "headline": {"main": "Genetic Mapping Triggers New Hope on Schizophrenia", "print_headline": "Genetic Mapping Triggers New Hope on Schizophrenia"}, "abstract": null, "print_page": null, "word_count": "721", "_id": "53cddbaf79881075cd5f2259", "snippet": "Scientists have linked more than 100 spots in our DNA to the risk of developing schizophrenia, casting light on the mystery of what makes the disease tick.", "source": "AP", "slideshow_credits": null, "web_url": "http://www.nytimes.com/aponline/2014/07/21/science/ap-us-sci-schizophrenia-genome.html", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [], "original": "By THE ASSOCIATED PRESS", "organization": "THE ASSOCIATED PRESS"}, "document_type": "article", "pub_date": "2014-07-21T23:30:00Z", "section_name": "Science"}, {"type_of_material": "News", "blog": [], "news_desk": "National", "lead_paragraph": "In declining to keep a prescription drug database, the state has hampered its ability to combat abuse and also drawn buyers from neighboring states.", "headline": {"main": "Missouri Alone in Resisting Prescription Drug Database", "print_headline": "Missouri Alone in Resisting Prescription Drug Database"}, "abstract": "Missouri remains only state in country that has declined to keep prescription drug database, primary tool used to identify people who acquire excess prescriptions for painkillers and other drugs; lack of database has put state at disadvantage in fight against prescription abuse and made it destination for addicts and dealers; state Legislature supports measure for database, but plan has been blocked by small group of lawmakers led by State Sen Rob Schaaf.", "print_page": "1", "word_count": "1924", "_id": "53cc6a577988106bbe89b1e8", "snippet": "In declining to keep a prescription drug database, the state has hampered its ability to combat abuse and also drawn buyers from neighboring states.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2014/07/21/us/missouri-alone-in-resisting-prescription-drug-database.html", "multimedia": [{"subtype": "wide", "url": "images/2014/07/21/us/JP-MISSOURI-2/JP-MISSOURI-2-thumbWide.jpg", "height": 126, "width": 190, "legacy": {"wide": "images/2014/07/21/us/JP-MISSOURI-2/JP-MISSOURI-2-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "type": "image"}, {"subtype": "xlarge", "url": "images/2014/07/21/us/JP-MISSOURI-2/JP-MISSOURI-2-articleLarge.jpg", "height": 400, "width": 600, "legacy": {"xlargewidth": "600", "xlarge": "images/2014/07/21/us/JP-MISSOURI-2/JP-MISSOURI-2-articleLarge.jpg", "xlargeheight": "400"}, "type": "image"}, {"subtype": "thumbnail", "url": "images/2014/07/21/us/MISSOURI/MISSOURI-thumbStandard.jpg", "height": 75, "width": 75, "legacy": {"thumbnailheight": "75", "thumbnail": "images/2014/07/21/us/MISSOURI/MISSOURI-thumbStandard.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"value": "Drugstores", "is_major": "N", "rank": "11", "name": "subject"}, {"value": "Archives and Records", "is_major": "N", "rank": "5", "name": "subject"}, {"value": "Mallinckrodt Pharmaceuticals", "is_major": "N", "rank": "8", "name": "organizations"}, {"value": "Logan, Richard", "is_major": "N", "rank": "10", "name": "persons"}, {"value": "Missouri", "is_major": "Y", "rank": "1", "name": "glocations"}, {"value": "OxyContin (Drug)", "is_major": "N", "rank": "12", "name": "subject"}, {"value": "Drug Abuse and Traffic", "is_major": "Y", "rank": "3", "name": "subject"}, {"value": "Schaaf, Robert", "is_major": "Y", "rank": "4", "name": "persons"}, {"value": "Sedatives", "is_major": "N", "rank": "7", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Pain-Relieving Drugs", "is_major": "N", "rank": "6", "name": "subject"}, {"value": "Drug Enforcement Administration", "is_major": "N", "rank": "9", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Alan", "lastname": "SCHWARZ"}], "original": "By ALAN SCHWARZ"}, "document_type": "article", "pub_date": "2014-07-21T00:00:00Z", "section_name": "U.S."}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial", "lead_paragraph": "Miracle cystic fibrosis treatment carries a heavy price.", "headline": {"main": "The $300,000 Drug", "kicker": "Op-Ed Columnist", "print_headline": "The $300,000 Drug", "content_kicker": "Op-Ed Columnist"}, "abstract": "Joe Nocera Op-Ed column holds that success of Kalydeco, drug proven highly effective in treating cystic fibrosis in small subset of sufferers, heralds era of personalized medicine; says that drug, which was developed by Vertex Pharmaceuticals and costs $300,000 yearly, also raises question of how society will pay for such treatments; points to role of drug companies in keeping prices high.", "print_page": "19", "word_count": "824", "_id": "53c9c5617988105969cada02", "snippet": "Miracle cystic fibrosis treatment carries a heavy price.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2014/07/19/opinion/joe-nocera-cystic-fibrosis-drug-price.html", "multimedia": [{"width": 75, "url": "images/2012/01/27/opinion/Nocera_New/Nocera_New-thumbStandard-v2.jpg", "height": 75, "subtype": "thumbnail", "legacy": {"thumbnailheight": "75", "thumbnail": "images/2012/01/27/opinion/Nocera_New/Nocera_New-thumbStandard-v2.jpg", "thumbnailwidth": "75"}, "type": "image"}], "subsection_name": null, "keywords": [{"rank": "1", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Vertex Pharmaceuticals Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Cystic Fibrosis", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Health Insurance and Managed Care", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "United States", "name": "glocations"}, {"rank": "6", "is_major": "N", "value": "Werth, Barry", "name": "persons"}, {"rank": "7", "is_major": "N", "value": "The Antidote: Inside the World of New Pharma (Book)", "name": "creative_works"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "firstname": "Joe", "rank": 1, "lastname": "NOCERA"}], "original": "By JOE NOCERA"}, "document_type": "article", "pub_date": "2014-07-19T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": null, "lead_paragraph": "First they removed the baby seat to make room in the car, and then three Israelis searched for an Arab to kidnap and kill to avenge the deaths of three Jewish teenagers, according to a murder indictment released on Thursday.", "headline": {"main": "Three Israelis Charged With Revenge Murder of Palestinian Teen", "print_headline": "Three Israelis Charged With Revenge Murder of Palestinian Teen"}, "abstract": null, "print_page": null, "word_count": "797", "_id": "53c7e5f179881073fd108b15", "snippet": "First they removed the baby seat to make room in the car, and then three Israelis searched for an Arab to kidnap and kill to avenge the deaths of three Jewish teenagers, according to a murder indictment released on Thursday.", "source": "Reuters", "slideshow_credits": null, "web_url": "http://www.nytimes.com/reuters/2014/07/17/world/middleeast/17reuters-palestinians-israel-teen.html", "multimedia": [], "subsection_name": "Middle East", "keywords": [], "byline": {"person": [], "original": "By REUTERS", "organization": "REUTERS"}, "document_type": "article", "pub_date": "2014-07-17T11:01:49Z", "section_name": "World"}, {"type_of_material": "News", "blog": [], "news_desk": "Business", "lead_paragraph": "While the drug, crenezumab, did not slow progression of the disease over all, at the highest doses it seemed to delay a decline in mental ability in patients with mild Alzheimer\u2019s.", "headline": {"main": "Roche Reports Mixed Results in Trial of an Alzheimer\u2019s Drug", "print_headline": "Mixed Results for Roche in Alzheimer\u2019s Drug Trial"}, "abstract": "Roche reports mixed results in its latest trial of Alzheimer's drug crenezumab.", "print_page": "4", "word_count": "743", "_id": "53c693c079881044e1d787bb", "snippet": "While the drug, crenezumab, did not slow progression of the disease over all, at the highest doses it seemed to delay a decline in mental ability in patients with mild Alzheimer\u2019s.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2014/07/17/business/roche-reports-mixed-results-in-trial-of-an-alzheimers-drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Alzheimer's Disease", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Clinical Trials", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "2", "name": "subject"}, {"value": "Roche Holding A G", "is_major": "Y", "rank": "4", "name": "organizations"}], "byline": {"contributor": "", "person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2014-07-17T00:00:00Z", "section_name": "Business Day"}, {"type_of_material": "News", "blog": [], "news_desk": null, "lead_paragraph": "New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.", "headline": {"main": "Studies See New Risks for Cholesterol Drug Niacin", "print_headline": "Studies See New Risks for Cholesterol Drug Niacin"}, "abstract": null, "print_page": null, "word_count": "758", "_id": "53c6eaa579881073fd108865", "snippet": "New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health. Some prominent doctors say the drug now seems too risky for routine use.", "source": "AP", "slideshow_credits": null, "web_url": "http://www.nytimes.com/aponline/2014/07/16/health/ap-us-med-niacin-health-risks.html", "multimedia": [], "subsection_name": null, "keywords": [], "byline": {"person": [], "original": "By THE ASSOCIATED PRESS", "organization": "THE ASSOCIATED PRESS"}, "document_type": "article", "pub_date": "2014-07-16T17:10:49Z", "section_name": "Health"}], "meta": {"hits": 6, "offset": 0, "time": 35}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}